Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is down over 35% to $4.83. AstraZeneca plc (ADR) (NYSE:AZN) reported that a phase III study to assess the efficacy and safety of drug applicant Fostamatinib for rheumatoid arthritis met one primary goal, while it missed …
↧